Biopterin analogs

Abstract

Abstract The compounds of formula (I) <IMAGE> (I) wherein R1 is hydrogen, lower alkyl of 1-4 carbons, lower alkenyl of 2-4 carbons, -B-X-R5)n, or -B-Z-B-X-R5-n; n=0 when X is halogen or n=1 when X is -O-, -NR6- (where R6 is hydrogen or lower alkyl of 1-4 carbons) or -S(O)q- (where q=0 to 2); B is lower alkanyl (straight or branched) of 1-5 carbons; R5 is hydrogen, aralkyl of 7 to 12 carbons or alkyl of 1-10 carbons; Z is -O-, NR6-, or -S(O)q-; R2 is hydrogen or lower alkyl of 1-4 carbons or lower alkenyl of 2-4 carbons or either R1 and R2 together with the carbon atom in the pteridine ring structures to which they are attached, form a spirocycloalkyl ring system having 3 to 7 carbon atoms; R3 and R4 are hydrogen or methyl; R2 and R3, together with the carbon atoms in the pteridine ring structure to which they are attached, form a cycloalkyl ring system having 5 to 7 carbon atoms; provided that at least one of R1, R2, R3 and R4 is hydrogen, and further provided that one of R1, R2 and R3, R4 represents gem disubstitution; have been found to selectively cofactor the biological conversion of tyrosine to dopamine, and are useful in the treatment of diseases resulting from a deficiency of dopamine in the brain such as Parkinson's disease. A further aspect of this invention comprises novel compounds of formula (I) defined above with the proviso that when both R3 and R4 are methyl neither R1 and R2 may be methyl, and R1 and R2 may not both be hydrogen, or a pharmaceutically acceptable salt thereof.

Inventors

• 👤 Charles A. Nichol
• 👤 John F. Reinhard, Jr.
• 👤 Gary K. Smith
• 👤 Eric C. Bigham

Bibliographic Details